
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol.
Sec. Cancer Metabolism
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1588290
This article is a correction to:
Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. [State the mistake which was made] The two figures above and below in Figure 1K-L, related to SOX2 staining, are part of a series of photographs aimed at demonstrating that GB explantssmall tissue fragments approximately 300 µm in size-retain the original cytoarchitecture of the tissue from which they are derived (surgery tissue). The upper figure represents an image of the surgery tissue, while the lower figure shows the corresponding small explant (GB-EXP) derived from it. The SOX2 staining was specifically performed to add further evidence of the preserved representation of tumor components within the GB explant, a conclusion also supported by other images in the series (GFAP; CD105,CD33).We acknowledge an error of duplication in the figures related to SOX2, as the upper image is, in fact, a photo of the same explant but with a slightly shifted area. We deeply regret this misplacement and are providing the correct image of the tumor stained with SOX2. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.Reminder: Figures, tables, and images will be published under a Creative Commons CC-BY licence and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.End of template, if you would like to request a correction for a reason not seen here, please contact the journal's Editorial Office
Keywords: Glioblastoma, predictive models, drug response, Metabolic imaging, precision medicine
Received: 05 Mar 2025; Accepted: 04 Apr 2025.
Copyright: © 2025 Morelli, Lessi, Barachini, Liotti, Montemurro, Perrini, Santonocito, Gambacciani, Snuderl, Pieri, Aquila, Farnesi, Naccarato, Viacava, Cardarelli, Ferri, Mulholland, Ottaviani, Paiar, Liberti, Pasqualetti, Menicagli, Aretini, Signore, Franceschi and Mazzanti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mariangela Morelli, Section of Genomics and Transcriptomics, Fondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy, San Giuliano Terme, Pisa, Italy
Chiara Maria Mazzanti, Section of Genomics and Transcriptomics, Fondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy, San Giuliano Terme, Pisa, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.